UK and Ireland News
2 December, 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
20 May, 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer
25 March, 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer
2020 Archive
2019 Archive
12 December, 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
2 October, 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment
21 June, 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test
4 June, 2019
Secondary Analysis of Landmark TAILORx Results, Published in
The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
25 March, 2019
Evidence from UK hospitals supports the value of the Oncotype DX test in avoiding unnecessary chemotherapy for patients with node-positive breast cancer
2018 Archive
2017 Archive
2016 Archive